My name is Alex and I am a 2021 NextGen Fellow with CDN. I am a student at California State University East Bay pursuing a BA in Business Administration with a focus on Operations and Supply Chain Management. As a person living with T1D for over 10 years, I understand that access to insulin and modern treatments is vital. One of my personal goals is to make resources more cost-effective and accessible to everyone.
My life purpose is deeply linked to Eli Lilly and Company’s (Lilly) Environmental, Social and Governance (ESG) initiative that launched in May 2021. I had the opportunity to interview Jim Greffet, head of the ESG Strategy at Lilly. Jim has worked at Lilly for 21 years. His wife has had T1D for 46 years now and she is the reason why Jim is passionate about his work at Lilly.
I asked Jim to tell me more about Lilly’s Insulin Value Program, which makes most Lilly insulins available in the U.S. for no more than $35 a month. Jim mentioned that Lilly has focused on insulin pricing and accessibility for a long time. The program began at the height of the COVID pandemic, when people started experiencing job loss and other life disruptions that made it difficult to afford insulin. Lilly created a downloadable copay card on their Insulin Affordability Solutions website. Once downloaded, you can bring the card, along with your prescription for Lilly insulin, to the pharmacy and pay only $35 for a one-month supply of insulin – regardless of your insurance status. Lilly realized that there is an ongoing need for this program, so these cards will continue to be available for the immediate future. Lilly has also expanded the program so people who use government insurance, like Medicare, are eligible. The card lasts for one year, but you can download a new card once the year is up so you can continue to access discounted medication.
In my talk with Jim, I emphasized that insulin is a global need and asked him if there are plans to implement similar programs outside the U.S. Jim said that specific needs and circumstances need to be considered at an individual country level first. He told me about a relationship between Lilly and a non-profit organization called Life for a Child that has helped them respond to international insulin access and needs. Lilly partnered with Life for a Child in 2009 and since then, they have helped about 23,000 children with diabetes and plan to expand that impact to 150,000 over the next 10 years. In addition, through the end of last year, Lilly donated almost 2.5 million vials of insulin to those in need.
As a woman who wants to work in the diabetes field, I asked Jim about Lilly’s commitment to advancing women (especially BIPOC) in their workforce. Jim explained that diversity, equity and inclusion are a priority for Lilly. Through our conversation, I learned about several characteristics and programs at Lilly that exist to help promote a more progressive work environment:
I also asked Jim whether Lilly has plans to become more eco-friendly. Jim told me that Lilly wants to be carbon neutral in their own operations by 2030. Their strategy includes the following components:
After talking with Jim, I was especially impressed by Lilly’s programs that affect people’s health and their adjustments in processes to become truly eco-friendly. Now, I really want to pursue a career at Lilly to be part of their holistic commitment. I thank Jim, and Lilly, for their openness and transparency in discussing how their ESG Strategy contributes to their people, the rest of society, and our planet.
Editor’s note: Lilly is a Corporate Member of The Diabetes Link.